Bio Protocol Secures $6.9M and Launches Bio V2 for Decentralized AI Research

The funding, led by Maelstrom Fund, supports the roll-out of on-chain fundraising tools, AI research agents, and BioXP incentive systems for the scientific community.

Summary

Bio Protocol, a decentralized science platform, raised $6.9 million in a round led by Maelstrom Fund, with Mechanism Capital, Animoca Brands, and Presto Labs participating. The company also introduced Bio V2, which offers on-chain fundraising, a decentralized AI research framework, and the BioXP incentive system. BioAgents, its AI-powered research tools, help generate hypotheses, secure funding for experiments, and monetize academic discoveries. The first BioAgent, launched with VitaDAO and Aubrey de Grey’s lab in August, has already raised over $250,000 for research and produced more than 1,000 longevity hypotheses.

Terms & Concepts
  • Decentralized Science (DeSci): A movement leveraging blockchain and decentralized technologies to fund, conduct, and share scientific research outside traditional institutional frameworks.
  • On-Chain Fundraising: A blockchain-based method of raising capital, making funding transparent, verifiable, and globally accessible.
  • AI Agents: Autonomous digital entities powered by artificial intelligence that can perform tasks such as data analysis, hypothesis generation, and research coordination without constant human oversight.